title: Cangrelor Use Since FDA Approval: A Single-Center, Real-World Experience at a Tertiary Care Hospital.
authors.forename: Muthiah
authors.initials: M
authors.lastname: Vaduganathan
authors.forename: Arman
authors.initials: A
authors.lastname: Qamar
authors.forename: Abhayjit
authors.initials: A
authors.lastname: Singh
authors.forename: Ramkumar V
authors.initials: RV
authors.lastname: Venkateswaran
authors.forename: Paul M
authors.initials: PM
authors.lastname: Szumita
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Croce
authors.forename: Laura
authors.initials: L
authors.lastname: Mauri
authors.forename: Jane A
authors.initials: JA
authors.lastname: Leopold
authors.forename: Pinak B
authors.initials: PB
authors.lastname: Shah
authors.forename: Piotr
authors.initials: P
authors.lastname: Sobieszczyk
authors.forename: David P
authors.initials: DP
authors.lastname: Faxon
authors.forename: Deepak L
authors.initials: DL
authors.lastname: Bhatt
mesh_terms: D000249:Adenosine Monophosphate / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000368:Aged; D003324:Coronary Artery Disease / Q000628:therapy*; D017277:Drug Approval; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007432:Intraoperative Period; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention; D058921:Purinergic P2Y Receptor Antagonists / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D062606:Tertiary Care Centers; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D058921:Purinergic P2Y Receptor Antagonists; D000249:Adenosine Monophosphate; C117446:cangrelor